Amyloid-beta 1–42
Amyloid-beta 1–42
Neurology, Aging & Mitochondria
Amyloid-beta 1–42 is indexed as endogenous/pathologic peptide in the PeptideBase article library. It is referenced in “Can Cyclic Peptides Tune TREM2? What the New Microglia Study Actually Shows” and 1 other PeptideBase article. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.
Deep Dives on Amyloid-beta 1–42
Start here for the plain-English articles connected to this peptide.
Can Cyclic Peptides Tune TREM2? What the New Microglia Study Actually Shows
A 2026 study found micromolar TREM2-binding cyclic peptides that altered amyloid-stressed microglial cell models—but did not test brain exposure, animal efficacy, or Alzheimer’s benefit.
Read articleWhen a Peptide Enters Phase 1: What That Actually Means
Recent KIT2014 and Nubytide/8M2D peptide trial updates are useful examples of how to read early clinical-development news: meaningful, but not proof that a peptide works, is approved, or belongs in wellness marketing.
Read articleQuick Facts
- Origin
- Named endogenous/pathologic peptide referenced in PeptideBase coverage
- Category
- Neurology, Aging & Mitochondria